Led · Equity · Jul 2024

Founded in 2017, iFollow develops collaborative autonomous robots (cobots) to assist order pickers in refrigerated and freezing warehouse environments. Its first product, the iLogistics robot, can carry up to 300 kg and operate at temperatures down to -25°C while adapting to different types of carts. The company says its solution delivers a minimum 30% productivity gain and improves picking quality and pre‑conditioning of orders. iFollow targets the demanding food‑logistics refrigerated market and is expanding into adjacent retail use cases with a developing iRetail autonomous cart for merchandising, stock analysis, and automatic replenishment. The startup has a team of about 10 people and has already signed Toupargel as a customer. The fundraise will be used to industrialize production, recruit technical and commercial staff, and deploy a target of 100 robots by the end of 2018. iFollow builds autonomous mobile robots (AMR) designed to facilitate order picking, transport heavy loads in warehouses and support supply-chain operations. The start-up employs around 40 people. After successful pilots, CEO Vincent Jacquemart says the objective is to scale up and commercialize their autonomous robot for logistics. With this financing, iFollow intends to take the next step toward marketing and broader deployment. Backers highlight a large addressable market—described as worth "tens of billions"—with at least 50,000 industrial sites in Europe and 100,000 industrial sites plus 30,000 warehouses worldwide. The company raised new capital to support that go-to-market and scaling effort.

Participated · Equity · Jul 2021

Flatsy provides a digital platform to manage property visits for real estate professionals and offers the option to outsource visits to independently selected and supported local agents called Flatguides. In 2023 the company expanded its offering to include entry and exit condition reports (états des lieux) and aims to be the first nationwide platform for property commercialisation. Flatsy serves traditional agencies, networks, neo-agencies and social landlords, and counts more than 300 clients including Sergic, Altarea, White Bird, Masteos and ICF Habitat. Operational metrics reported include over 200 active agents, 50,000 properties entrusted and nearly 300,000 visits completed; the company employs more than 40 people and is present in about fifteen French cities including Paris, Nantes, Strasbourg, Bordeaux, Marseille and Lyon. The business has grown roughly 60% per year since 2019. Flatsy recently raised €3.5M to continue product development, add service modules and expand geographically, with plans to open 10 new cities and quintupling its number of agents by the end of 2026. Flatsy offers a digital tool that helps real-estate professionals manage property visits. The platform centralizes all appointments and enables delegation of visits to independent agents. It aims to digitalize the real-estate sector and improve visit-management workflows. With this new funding, Flatsy plans to further develop its appointment-booking and dossier-management tools. The company intends to hire about twenty employees and to expand into roughly ten additional cities.

Led · Equity · Feb 2021

SCALINX designs semiconductor chips aimed at the defense and telecommunications sectors. The company positions its technology to facilitate deployment of 5G and 6G networks and, in the future, autonomous mobility. It operates in a strategic area linked to national and European sovereignty. SCALINX recently raised €34 million from investors including French Tech Souveraineté, GO CAPITAL, Bertrand Distinguin and Thales (Patrice Caine). The fundraising occurs amid increased French and EU support for the semiconductor industry under initiatives such as the Chips Act. SCALINX is a fabless semiconductor company that designs advanced signal conversion chips, including ADCs and DACs, using its proprietary Smart Conversion CORE (SCCORE™) technology. Its solutions target wider analog bandwidth, lower power consumption, and higher integration for high-speed, medium-to-high resolution data conversion. Target applications include communications infrastructure, RADAR, and test & measurement equipment, with relevance to mmWave communications and the 5G transformation. SCALINX plans to increase capacity, enter new markets, and expand its team to meet growing customer demand. The company was founded in 2015 and is headquartered in Paris, with additional design centers in Caen and Grenoble. It was also selected as a 2020 winner of the France Relance call for projects.

Led · Series C · Jul 2020

LumiThera is a Seattle-based commercial-stage medical device company developing the Valeda Light Delivery System, a multi-wavelength photobiomodulation (PBM) treatment for ocular disorders including dry age-related macular degeneration (AMD) and diabetic retinopathy. The company has been granted CE Mark authorization for Valeda in the European Economic Area, but Valeda is not approved by the U.S. Food & Drug Administration. LumiThera is completing enrollment in two prospective, randomized, double-masked clinical trials: LIGHTSITE II in Europe and LIGHTSITE III in the U.S., and is planning additional trials for diabetic macular edema and AMD. It raised approximately $14M in a Series C financing. The company intends to use the proceeds to commercialize Valeda, complete LIGHTSITE III enrollment, and pursue U.S. regulatory clearance. Led by President and CEO Clark Tedford, Ph.D., LumiThera focuses on office-based PBM treatments delivered by eye care specialists. LumiThera is a Seattle-based clinical-stage medical device company developing non-invasive photobiomodulation (PBM) treatments for ocular disorders using light-emitting diodes. Its lead product is the LT-300, an ophthalmologist LED office-based instrument being developed to treat dry age-related macular degeneration (AMD). The company is conducting the LIGHTSITE I study, a prospective, randomized, double-masked clinical trial in 30 dry AMD subjects using the LT-300 light delivery system. LumiThera plans to use recently raised funds to further develop the LT-300, pursue regulatory clearances in select countries outside the USA including the CE mark in Europe, and expand clinical and commercial activities. The company completed a $5.5M Series B round led by WaterStone Capital with participation from RPR Venture. Clark Tedford, Ph.D., serves as President and CEO.